Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
ONCOTELIC THERAPEUTICS, INC.
AI Executive Summary
AI-powered analysis of 8-K filing content
Oncotelic Therapeutics entered into a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics on March 31, 2026, to develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing by integrating TechForce's hardware with Oncotelic's proprietary PDAOAI Platform.
Key Takeaways
Strategic partnership combines TechForce's robotic hardware expertise with Oncotelic's proprietary PDAOAI Platform for pharmaceutical manufacturing applications
Agreement includes non-exclusive licensing of Oncotelic's intellectual property to TechForce for joint development and manufacturing
2 more takeaways